Overview

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Status:
RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
Phase:
PHASE2
Details
Lead Sponsor:
Teikoku Pharma USA, Inc.